EP1644403B1 - Cytotoxic depsipeptides - Google Patents

Cytotoxic depsipeptides Download PDF

Info

Publication number
EP1644403B1
EP1644403B1 EP04743045A EP04743045A EP1644403B1 EP 1644403 B1 EP1644403 B1 EP 1644403B1 EP 04743045 A EP04743045 A EP 04743045A EP 04743045 A EP04743045 A EP 04743045A EP 1644403 B1 EP1644403 B1 EP 1644403B1
Authority
EP
European Patent Office
Prior art keywords
substituted
unsubstituted
independently selected
groups
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP04743045A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1644403A2 (en
Inventor
Paco Instituto Biomar S.A. ROMERO
Leyre Instituto Biomar S.A. MALET
Librada Maria Instituto Biomar S.A. CANEDO
Carmen Pharma Mar S.A. CUEVAS
José Pharma Mar S.A. FERNANDO REYES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instituto Biomar SA
Original Assignee
Instituto Biomar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instituto Biomar SA filed Critical Instituto Biomar SA
Priority to PL04743045T priority Critical patent/PL1644403T3/pl
Publication of EP1644403A2 publication Critical patent/EP1644403A2/en
Application granted granted Critical
Publication of EP1644403B1 publication Critical patent/EP1644403B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Definitions

  • the present invention relates to new depsipeptide compounds, pharmaceutical compositions containing them and their use as antitumoural agents.
  • JP 11180997 discloses an antitumour compound of formula which is obtained from Streptomyces nobilis. Its IC 50 in Hela S3 cells is 14 nM.
  • Cancer is a leading cause of death in animals and humans.
  • Several efforts have been and are still being undertaken in order to obtain an antitumour agent active and safe to be administered to patients suffering from a cancer.
  • the problem to be solved by the present invention is to provide compounds that are useful in the treatment of cancer.
  • the present invention is directed to compounds of general formula I or pharmaceutically acceptable salts or stereoisomers thereof: wherein
  • the present invention also relates to the obtaining of the compounds of formula I , including the compound we call IB-01211 which is of formula:
  • IB-01211 can be obtained from a strain of microorganism capable of producing it.
  • the preferred process comprises the steps of cultivating a strain of microorganisms capable of producing IB-01211 in an aqueous nutrient medium with assimilable carbon and nitrogen sources and salts, under controlled submerged aerobic conditions, and then recovering and purifying the compound from the cultured broth.
  • oxazole/thiazole/imidazole fragment of the compounds of the present invention can be synthesised by using the teaching of the following literature: Panek J. S. et al. "Studies directed toward the synthesis of Ulapualide A. Asymmetric Synthesis of the C8-C25 tris-oxazole fragment” J. Org. Chem. 1996, 61, 6496-6497 ; Panek J. S. et al. "Studies directed toward the total synthesis of kabiramide C: asymmetric synthesis of the C7-C19 fragment” Tetrahedron Lett.
  • compounds of formula I including IB-01211 can be made by coupling of the following components: where R 1 , R 2 , R 3 , R 4 are as defined, Prot OH is an optional protecting group for hydroxy, and Prot NH is an optional protecting group for amino.
  • the respective protecting groups can be replaced by other reactive groups to encourage the desired coupling, which typically takes place sequentially first to join the oxazole/thiazole/imidazole fragment to one end of the amino acidic fragement, and then to close the ring.
  • the present invention is directed to pharmaceutical compositions containing a compound of formula I or pharmaceutically acceptable salts or stereoisomers thereof, together with a pharmaceutically acceptable carrier or diluent.
  • the present invention is also directed to the use of compounds of formula I or pharmaceutically acceptable salts or stereoisomers thereof in the preparation of a medicament for the treatment of cancer.
  • the present invention relates to compounds of general formula I as defined above.
  • Alkyl and alkoxy groups preferably have from 1 to 12 carbon atoms.
  • One more preferred class of alkyl groups has 1 to about 8 carbon atoms, yet more preferably 1 to about 6 carbon atoms, and most preferably 1, 2, 3 or 4 carbon atoms.
  • Methyl, ethyl, propyl including isopropyl, and butyl including isobutyl, sec-butyl and terc-butyl are particularly preferred alkyl groups in the compounds of the present invention.
  • the term alkyl unless otherwise modified, refers to both cyclic and noncyclic groups, although cyclic groups will comprise at least three carbon ring members.
  • Alkylidene groups may be branched or unbranched and preferably have from 1 to 12 carbon atoms.
  • One more preferred class of alkylidene groups has from 1 to about 8 carbon atoms, yet more preferably from 1 to about 6 carbon atoms, and most preferably 1, 2, 3 or 4 carbon atoms.
  • Methylidene, ethylidene and propylidene including isopropylidene are particularly preferred alkylidene groups in the compounds of the present invention.
  • alkenyl and alkynyl groups in the compounds of the present invention have one or more unsaturated linkages and from 2 to about 12 carbon atoms, more preferably 2 to about 8 carbon atoms, still more prefereably 2 to about 6 carbon atoms, even more prefereably 1, 2, 3 or 4 carbon atoms.
  • alkenyl and alkynyl as used herein refer to both cyclic and noncyclic groups, although straight or branched noncyclic groups are generally more preferred. In a general sense, we include alkylidene within alkenyl, they both being substituents with a double bond.
  • Suitable aryl groups in the compounds of the present invention include single and multiple ring compounds, including multiple ring compounds that contain separate and/or fused aryl groups.
  • Typical aryl groups contain from 1 to 3 separated or fused rings and from 6 to about 18 carbon ring atoms.
  • Specifically preferred aryl groups include substituted or unsubstituted phenyl, naphthyl, biphenyl, phenanthryl and anthracyl.
  • Suitable acyl groups include alkanoyl groups which have from 2 to about 12 carbon atoms, more preferably from 2 to about 8 carbon atoms, still more preferably from 2 to about 6 carbon atoms, even more preferably 2 carbon atoms.
  • Other acyl groups include alkenylacyl, alkynylacyl, arylacyl, heterocyclylacyl.
  • Suitable heterocyclic groups include heteroaromatic and heteroalicyclic groups.
  • Suitable heteroaromatic groups in the compounds of the present invention contain one, two or three heteroatoms selected from N, O or S atoms and include, e.g., coumarinyl including 8-coumarinyl, quinolinyl including 8-quinolinyl, pyridyl, pyrazinyl, pyrimidyl, furyl, pyrrolyl, thienyl, thiazolyl, oxazolyl, imidazolyl, indolyl, benzofuranyl and benzothiazol.
  • Suitable heteroalicyclic groups in the compounds of the present invention contain one, two or three heteroatoms selected from N, O or S atoms and include, e.g., tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, morpholino and pyrrolindinyl groups.
  • suitable groups such as OR', SR
  • Suitable halogen substituents in the compounds of the present invention include F, Cl, Br and I.
  • pharmaceutically acceptable salts refers to any pharmaceutically acceptable salt, ester, solvate, hydrate or any other compound which, upon administration to the patient is capable of providing (directly or indirectly) a compound as described herein.
  • non-pharmaceutically acceptable salts also fall within the scope of the invention since those may be useful in the preparation of pharmaceutically acceptable salts.
  • the preparation of salts can be carried out by methods known in the art.
  • salts of compounds provided herein are synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
  • such salts are, for example, prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent or in a mixture of the two.
  • nonaqueous media like ether, ethyl acetate, ethanol, isopropanol or acetonitrile are preferred.
  • acid addition salts include mineral acid addition salts such as, for example, hydrochloride, hydrobromide, hydroiodide, sulphate, nitrate, phosphate, and organic acid addition salts such as, for example, acetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, methanesulphonate and p-toluenesulphonate.
  • mineral acid addition salts such as, for example, hydrochloride, hydrobromide, hydroiodide, sulphate, nitrate, phosphate
  • organic acid addition salts such as, for example, acetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, methanesulphonate and p-toluenesulphonate.
  • alkali addition salts include inorganic salts such as, for example, sodium, potassium, calcium and ammonium salts, and organic alkali salts such as, for example, ethylenediamine, ethanolamine, N,N-dialkylenethanolamine, triethanolamine and basic aminoacids salts.
  • the compounds of the invention may be in crystalline form either as free compounds or as solvates (e.g. hydrates) and it is intended that both forms are within the scope of the present invention.
  • Methods of solvation are generally known within the art.
  • the compounds of the present invention represented by the above described formula I may include enantiomers depending on their asymmetry or diastereoisomers.
  • the single isomers and mixtures of the isomers fall within the scope of the present invention.
  • Preferred compounds of the invention are those of general formula II wherein R 1 , R 2 , R 3 and R 4 groups have the same meaning as defined above.
  • Preferred R 1 groups are substituted or unsubstituted alkyl and substituted or unsubstituted alkylidene, more preferred are substituted or unsubstituted C 1 -C 6 alkyl and substituted or unsubstituted C 1 -C 6 alkylidene, still more preferred are isopropyl, sec-butyl and methylene.
  • Preferred R 2 groups are H and substituted or unsubstituted alkyl, and more preferred is H.
  • Preferred R 3 groups are H and substituted or unsubstituted aryl, and more preferred are H and phenyl.
  • Preferred R 4 group is O.
  • One particularly preferred compound of formula I is compound IB-01211:
  • Compound IB-01211 is preferably obtained from an actinomycete, named strain ES7-008.
  • strain ES7-008 A culture of this strain has been deposited in the Colecissus Espa ⁇ ola de Cultivos Tipo at the University of Valencia, in Spain, under the accession number CECT 3358. This deposit has been made under the provisions of the Budapest Treaty.
  • the microorganism strain ES7-008 is phylogenetically close to Thermoactinomyces genus.
  • the organism was isolated from an unidentified marine sponge.
  • the taxonomic methods were as follows.
  • the strain ES7-008 can utilize glucose, melibiose, xylose, and ethanol as carbon sources. Growth was poor on fructose, sucrose, rhamnose, and galactose. The organism did not grow on arabinose, mannose or myo-inositol.
  • meso-2,6-diaminopimelic acid was present in the whole hydrolysated cell of strain ES7-008
  • the mayor fatty acids were identified as i-15:0, a-15:0, 15:0, i-16:0, i-17:1, i-17:0, and a-17:0.
  • the fatty acids composition of strain ES7-008 and other actinomycete strains is in the following table, where the composition is given as percentage of total fatty acids content.
  • the whole cell sugar pattern did not show a specific profile
  • Partial sequence of 16S rDNA was performed following standard procedures. The DNA of the organism was extracted after homogenization under liquid nitrogen. The 16S rDNA gene was amplified by the polymerase chain reaction using the eubacterial primers 27f and 1492r. The partial sequences were obtained using the primers 357r, 926r, and 1492r. All the primers used in this work were described by Lane, D.J. Nucleic acid techniques in bacterial systematics:115, 1991 . The partial sequence obtained was:
  • ES7-008 produces compound IB-01211 when it is cultured under controlled conditions in a suitable medium.
  • This strain is preferably grown in an aqueous nutrient medium, under aerobic and mesophilic conditions, preferably at 28°C-40°C and at a pH ranging between 6.0 and 8.0.
  • a wide variety of liquid culture media can be used for the cultivation of the organism.
  • Useful media are those that include an assimilable carbon source, such as starch, dextrin, sugar molasses, glucose, an assimilable nitrogen source such as protein, hydrolysed protein, defatted meals, corn steep, and useful inorganic anions and cations such a sodium, magnesium, potassium, ammonium, sulfate, chloride, phosphate, carbonate.
  • Trace elements may be added also. Aeration is preferably achieved by supplying air to the fermentation medium. Agitation is provided by a mechanical impeller. Conventional fermentation tanks have been found to be well suited for carrying out the cultivation of this organism. The addition of nutrients and pH control as well as antifoaming agents during the different stages of fermentation may be needed for increasing production and avoiding foaming.
  • Compound IB-01211 can be produced starting with a frozen lyophilized mycelium of ES7-008.
  • a mycelial mass is obtained by culturing the initial cells in shake flasks with a culture medium containing some of the ingredients described above at mesophilic temperatures and in aerobic conditions. This step may be repeated several times as needed and the material collected will be used as an inoculum to seed one or several fermentation tanks with the appropriate culture medium. If it is desired these tanks can be used for developing the inoculum or for the production stage, depending on the broth volume needed. Sometimes the production medium may be different than the ones used for inoculum development. Typical media are disclosed that can be used for inoculum development and for production of IB-01211 are in the following table.
  • Production of IB-O1211 can be monitored by whole broth assay against murine leukemia P-388 or by HPLC.
  • Compound IB-01211 can be isolated from the mycelial cake by extraction with a suitable mixture of solvents such as CHCl 3 :CH 3 OH:H 2 O. The activity is concentrated in the lower layer. The extracts from two repeated extraction can be combined and evaporated to dryness in vacuo.
  • Fractionation can be guided by the antitumour activity of fractions, by TLC visualized with vanillin in concentrated H 2 SO 4 or by analytical HPLC with photodiode-array and MS detector.
  • HPLC analysis is performed at room temperature using an analytical column Symmetry C18 (5 ⁇ ) and a MeOH:H 2 O:HOAc 95:5:1 mobile phase at a flow rate of 0.3 ml/min and plotted at 260 nm. In this conditions the IB-01211 retention time is 5.1 min as it is shown in Fig.9.
  • compositions comprising a compound of this invention or a pharmaceutically acceptable salt or stereoisomer thereof with a pharmaceutically acceptable carrier.
  • compositions include any solid (tablets, pills, capsules, granules, etc.) or liquid (solutions, suspensions or emulsions) suitable composition for oral, topical or parenteral administration.
  • compositions containing compounds of the invention may be delivered by liposome or nanosphere encapsulation, in sustained release formulations or by other standard delivery means.
  • Administration of the compounds or compositions of the present invention may be by any suitable method, such as intravenous infusion, oral preparations, intraperitoneal and intravenous administration.
  • infusion times of up to 24 hours are used, more preferably 1-12 hours, with 2-6 hours most preferred. Short infusion times which allow treatment to be carried out without an overnight stay in hospital are especially desirable. However, infusion may be 12 to 24 hours or even longer if required. Infusion may be carried out at suitable intervals of say 1 to 4 weeks.
  • the correct dosage of the compounds will vary according to the particular formulation, the mode of application, and the particular situs, host and tumour being treated. Other factors like age, body weight, sex, diet, time of administration, rate of excretion, condition of the host, drug combinations, reaction sensitivities and severity of the disease shall be taken into account. Administration can be carried out continuously or periodically within the maximum tolerated dose.
  • the compounds and compositions of the invention may be used with other drugs to provide a combination therapy.
  • the other drugs may form part of the same composition, or be provided as a separate composition for administration at the same time or at different time.
  • Inoculum development a frozen culture of ES7-008 or a well grown slant culture (5% vol.) is used to seed 100 ml of a seed medium, as described in Table 1, that it is contained in a 250 ml shake flask. The flask is incubated during 48 h. A 2 l Erlenmeyer flask with 500 ml of the same medium is seeded with 10% vol. of the first stage inoculum. The flask is incubated during 48h.
  • Fermentation step 50 l of production medium, as described in Table 1, contained in a 75 l fermentation tank are seeded with 2.5 l of second stage inoculum. The fermentation is carried out during 96 h with 400 rpm agitation and an air flow of 0.5V/V.M.
  • the extract was applied to a silica gel VFC (vacuum flash chromatography) system, using a mixture of n-hexane-EtOAc and EtOAc-MeOH as eluting solvents.
  • the fractions with antitumour activity, containing IB-01211 (900 mg) were eluted with EtOAc-MeOH 1:1, EtOAc-MeOH 1:3 and methanol.
  • the active fractions were chromatographied twice with a silica gel column using CHCl 3 -MeOH and EtOAc-MeOH mixtures as eluting solvents.
  • the cytotoxic activity was detected in fractions eluted with CHCl 3 -MeOH 96:4 in the first chromatography (200 mg of pure compound IB-01211) and in fractions eluted with EtOAc-MeOH 85:15-8:2 in the second chromatography (60 mg of pure compound IB-01211). Further purification with C18 reversed phase chromatography afforded 22 mg of pure compound IB-01211 eluted with MeOH.
  • the UV spectrum shows absorption at 225 nm, 265 nm and 290 nm as reported in Fig. 1.
  • the infrared absorption spectrum is shown in Fig. 2 of the accompanying drawings.
  • the 1 H NMR, 13 C NMR and DEPT spectra of IB-01211 are reported in Fig.3, Fig.4 and Fig. 5, respectively.
  • the 2D NMR experiments COSY, HMQC and HMBC are reported in Fig. 6, Fig. 7 and Fig. 8, respectively.
  • the ES-MS spectrum of IB-01211 displays a (M+Na) peak at 731 as reported in Fig. 9.
  • the finality of these assays is to interrupt the growth of an " in vitro" tumour cell culture by means a continued exhibition of the cells to the sample to be testing.
  • the following human cell lines were used: CELL LINES Name N° ATCC Tissue Characteristics K-562 CCL-243 leukemia erythroleukemia (pleural effusion) A-549 CCL-185 lung lung carcinoma "NSCL” SK-MEL-28 HTB-72 melanoma malignant melanoma HT-29 HTB-38 colon colon adenocarcinoma DU-145 HTB-81 prostate prostate carcinoma, not androgen receptors LNCaP CRL-1740 prostate prostate adenocarcinoma, with androgen receptors PC-3 CRL-1435 prostate prostate adenocarcinoma BT-474 HTB-20 breast breast adenocarcinoma MX-1 breast breast adenocarcinoma, Hs746t HTB-135 gastric stomach carcinoma SK-HEP-1 HTB-52
  • Tetrazolium Assay MTS is based on metabolic reduction of MTS to solubilized formazan crystals by the metabolically active mitochondria of living cells. For this reason, the methodology includes counting of the cell lines based on viability staining to ensure that cell concentrations are corrected to allow for 100% living cells into each well in lieu of Coulter counting or estimated dilutions based on standard growth curves.
  • tumour cell lines MX-1 (breast), HT-29 (colon), and LX-1 (non-small cell lung), respectively, were implanted subcutaneously into separate groups of recipient female athymic mice as a small seedling of approximately 2-3 mm 3 .
  • Each tumour type was then allowed to grow inside the animal to reach a group mean size of 100 ⁇ 15 mm 3 , at which time tumour-bearing mice were randomized into groups (Staging Day). The Staging Day also coincided with Day 0 for drug dosing.
  • test article was administered as a single intravenous ( iv ) bolus injection (i.e., QDx1) on the Staging Day (Day 0).
  • Tumour burden was determined for all animals throughout the study using a caliper, and the frequency was at least twice per week.
  • Protocols and criteria for drug activity were derived from those established by the National Cancer Institute for tumour systems similar to those used in these studies (NIH Publication No. 84-2635, In vivo cancer models 1976-1982).
  • Statistical analysis of tumour volumes for each group of drug treated animals was performed according to the Mann Whitney nonparametric test based on comparisons to the vehicle control cohort within the same experiment.
  • Results from tumour xenografts are tabulated below.
  • the average volume of the tumour mass was 100 ⁇ 15 mm 3 and the "net tumour growth" is really a difference between the size of the tumour on Day X and that on Day 0.
  • the parameter S.E.M. is commonly used in statistics and stands for standard error of the mean in a distribution of N (size) experimental values.
  • the compound IB01211 with a corresponding maximum tolerated dose (MTD) of 3.5 mg/kg in conventional CD-1 mice, demonstrated significant antitumour effect in vivo against a human non-small cell lung tumour at a dose of 0.43 MTD, and showed a trend to significance against breast tumour at a dose of 0.29 MTD, but not against colon tumour at a dose of 0.14 MTD.
  • MTD maximum tolerated dose

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP04743045A 2003-06-24 2004-06-23 Cytotoxic depsipeptides Expired - Lifetime EP1644403B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL04743045T PL1644403T3 (pl) 2003-06-24 2004-06-23 Cytotoksyczne depsypeptydy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0314726.1A GB0314726D0 (en) 2003-06-24 2003-06-24 New cytotoxic depsipeptides
PCT/GB2004/002694 WO2005000880A2 (en) 2003-06-24 2004-06-23 Cytotoxic depsipeptides

Publications (2)

Publication Number Publication Date
EP1644403A2 EP1644403A2 (en) 2006-04-12
EP1644403B1 true EP1644403B1 (en) 2007-12-12

Family

ID=27637250

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04743045A Expired - Lifetime EP1644403B1 (en) 2003-06-24 2004-06-23 Cytotoxic depsipeptides

Country Status (20)

Country Link
US (1) US7446094B2 (pt)
EP (1) EP1644403B1 (pt)
JP (1) JP4554606B2 (pt)
KR (1) KR20060035633A (pt)
CN (1) CN100448889C (pt)
AT (1) ATE380821T1 (pt)
AU (1) AU2004251103A1 (pt)
CA (1) CA2529371A1 (pt)
DE (1) DE602004010667T2 (pt)
DK (1) DK1644403T3 (pt)
EA (1) EA010585B1 (pt)
ES (1) ES2297441T3 (pt)
GB (1) GB0314726D0 (pt)
IL (1) IL172538A (pt)
MX (1) MXPA05013946A (pt)
NO (1) NO20060361L (pt)
NZ (1) NZ544066A (pt)
PL (1) PL1644403T3 (pt)
PT (1) PT1644403E (pt)
WO (1) WO2005000880A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006160723A (ja) * 2004-11-10 2006-06-22 Marine Biotechnol Inst Co Ltd 抗腫瘍活性を有する化合物及びその製造方法
US8093235B2 (en) 2006-04-25 2012-01-10 Rutgers, The State University Of New Jersey Macrocyclic compounds which stabilize G-Quadruplex DNA and RNA
WO2009018551A2 (en) 2007-08-02 2009-02-05 Rutgers, The State University Of New Jersey Therapeutic compounds
CA2780145A1 (en) 2009-11-05 2011-05-12 Rutgers, The State University Of New Jersey Therapeutic compounds
US20120302613A1 (en) * 2011-05-26 2012-11-29 Novobiotic Pharmaceuticals Llc Novel antibiotics
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
US11643438B2 (en) 2018-07-20 2023-05-09 The Board Of Regents Of The University Of Oklahoma Antimicrobial peptides and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11180997A (ja) * 1997-12-24 1999-07-06 Yamanouchi Pharmaceut Co Ltd 新規抗腫瘍化合物

Also Published As

Publication number Publication date
DK1644403T3 (da) 2008-05-05
JP4554606B2 (ja) 2010-09-29
CN1839148A (zh) 2006-09-27
EP1644403A2 (en) 2006-04-12
IL172538A0 (en) 2006-04-10
GB0314726D0 (en) 2003-07-30
EA200600092A1 (ru) 2006-06-30
CA2529371A1 (en) 2005-01-06
IL172538A (en) 2010-02-17
NZ544066A (en) 2008-04-30
WO2005000880A2 (en) 2005-01-06
AU2004251103A1 (en) 2005-01-06
CN100448889C (zh) 2009-01-07
US20070082878A1 (en) 2007-04-12
DE602004010667T2 (de) 2008-12-11
PL1644403T3 (pl) 2008-05-30
MXPA05013946A (es) 2006-03-09
PT1644403E (pt) 2008-03-12
KR20060035633A (ko) 2006-04-26
DE602004010667D1 (de) 2008-01-24
US20080227765A9 (en) 2008-09-18
JP2007536196A (ja) 2007-12-13
ES2297441T3 (es) 2008-05-01
EA010585B1 (ru) 2008-10-30
WO2005000880A3 (en) 2005-08-04
NO20060361L (no) 2006-03-08
US7446094B2 (en) 2008-11-04
ATE380821T1 (de) 2007-12-15

Similar Documents

Publication Publication Date Title
US4990448A (en) Bu-4061T
EP1644403B1 (en) Cytotoxic depsipeptides
KR920006881B1 (ko) 프리파스타틴(plipastatin)의 제조방법
US6852715B1 (en) Indolocarbazole alkaloids from a marine actinomycete
US7470714B2 (en) GM-95-containing antitumor effect potentiator, combined antitumor preparation and antitumor agent
JPH0213392A (ja) ペプチド抗生物質
JP2001512733A (ja) 抗腫瘍活性を有するマクロライド剤
EP0894092B1 (en) A cyclic hepta-peptide derivative from colonial ascidians, lissoclinum sp.
USH1638H (en) Use of the polypeptide compound
EP1254161B1 (en) Aerothricin analogs, their preparation and use
US20040033940A1 (en) Cyclic hepta-peptide derivative from colonial ascidians, lissoclinum SP
EP2025758A1 (en) NOVEL ANTIBIOTICS, BISPOLIDES A1, A2 AND A3 AND BISPOLIDES B1, B2a, B2b AND B3 AND METHOD FOR PRODUCING THE ANTIBIOTICS
JPH06228185A (ja) Ｄ３２９物質とその誘導体，その製造法及び用途
WO2004012756A1 (en) New cytotoxic cyclopeptide and its use for the treatment of cancer
WO2012062906A1 (en) Peptides as bioactive compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060124

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MALET, LEYREINSTITUTO BIOMAR S.A.

Inventor name: CUEVAS, CARMEN,PHARMA MAR, S.A.

Inventor name: FERNANDO REYES, JOSEPHARMA MAR, S.A.

Inventor name: CANEDO, LIBRADA, MARIAINSTITUTO BIOMAR S.A.

Inventor name: ROMERO, PACOINSTITUTO BIOMAR S.A.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ROMERO, PACOINSTITUTO BIOMAR S.A.

Inventor name: FERNANDO REYES, JOSEPHARMA MAR, S.A.

Inventor name: CUEVAS, CARMEN,PHARMA MAR, S.A.

Inventor name: MALET, LEYREINSTITUTO BIOMAR S.A.

Inventor name: CANEDO, LIBRADA, MARIAINSTITUTO BIOMAR S.A.

17Q First examination report despatched

Effective date: 20070118

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 5/097 20060101AFI20070601BHEP

Ipc: A61P 35/00 20060101ALI20070601BHEP

Ipc: C12P 21/04 20060101ALI20070601BHEP

Ipc: A61K 38/06 20060101ALI20070601BHEP

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602004010667

Country of ref document: DE

Date of ref document: 20080124

Kind code of ref document: P

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20080228

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: RITSCHER & PARTNER AG

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20080400700

Country of ref document: GR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2297441

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20071212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071212

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E003046

Country of ref document: HU

ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071212

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071212

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20080529

Year of fee payment: 5

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20080702

Year of fee payment: 5

26N No opposition filed

Effective date: 20080915

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080312

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090630

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20100625

Year of fee payment: 7

Ref country code: ES

Payment date: 20100628

Year of fee payment: 7

Ref country code: FI

Payment date: 20100629

Year of fee payment: 7

Ref country code: FR

Payment date: 20100630

Year of fee payment: 7

Ref country code: HU

Payment date: 20100616

Year of fee payment: 7

Ref country code: IE

Payment date: 20100625

Year of fee payment: 7

Ref country code: PT

Payment date: 20100608

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20100603

Year of fee payment: 7

Ref country code: CZ

Payment date: 20100604

Year of fee payment: 7

Ref country code: IT

Payment date: 20100624

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20100630

Year of fee payment: 7

Ref country code: CH

Payment date: 20100625

Year of fee payment: 7

Ref country code: NL

Payment date: 20100624

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20100629

Year of fee payment: 7

Ref country code: GB

Payment date: 20100625

Year of fee payment: 7

Ref country code: SE

Payment date: 20100629

Year of fee payment: 7

Ref country code: TR

Payment date: 20100607

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20100628

Year of fee payment: 7

Ref country code: PL

Payment date: 20100621

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090623

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20111223

BERE Be: lapsed

Owner name: INSTITUTO BIOMAR S.A.

Effective date: 20110630

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20120101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110623

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110623

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111223

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20110623

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110623

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110623

REG Reference to a national code

Ref country code: GR

Ref legal event code: ML

Ref document number: 20080400700

Country of ref document: GR

Effective date: 20120105

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 380821

Country of ref document: AT

Kind code of ref document: T

Effective date: 20110623

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20120229

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110630

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602004010667

Country of ref document: DE

Effective date: 20120103

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110630

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110630

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110623

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110624

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110630

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120103

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120105

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110623

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20120717

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110624

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110623

REG Reference to a national code

Ref country code: PL

Ref legal event code: LAPE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110624

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110623